Table 2.

Treatment-emergent related adverse events by system organ class, preferred term and worst severity; safety population treated with lisavanbulin 70 mg/m²

System Organ Class / Preferred Term, n (%)	Phase 1		Phase 2a				Total (N = 32)
	Solid tumors (N = 9)		Ovarian cancer (N = 11)		Glioblastoma (N = 12)
	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4
All adverse events	6 (67)	2 (22)	6 (55)	3 (27)	3 (25)	1 (8)	15 (47)	6 (19)
General disorders and administration site conditions	5 (56)	0	4 (36)	0	1 (8)	0	10 (31)	0
Fatigue	4 (44)	0	4 (36)	0	1 (8)	0	9 (28)	0
Chest pain	0	0	1 (9)	0	0	0	1 (3)	0
Gait disturbance	0	0	1 (9)	0	0	0	1 (3)	0
Pyrexia	1 (11)	0	0	0	0	0	1 (3)	0
Metabolism and nutrition disorders	4 (44)	0	3 (27)	0	2 (17)	0	9 (28)	0
Decreased appetite	1 (11)	0	1 (9)	0	1 (8)	0	3 (9)	0
Hypokalaemia	1 (11)	0	1 (9)	0	1 (8)	0	3 (9)	0
Hyponatraemia	2 (22)	0	1 (9)	0	0	0	3 (9)	0
Dehydration	1 (11)	0	1 (9)	0	0	0	2 (6)	0
Gastrointestinal disorders	4 (44)	0	3 (27)	0	1 (8)	0	8 (25)	0
Diarrhoea	2 (22)	0	2 (18)	0	0	0	4 (13)	0
Abdominal pain	1 (11)	0	2 (18)	0	0	0	3 (9)	0
Nausea	1 (11)	0	1 (9)	0	1 (8)	0	3 (9)	0
Constipation	0	0	2 (18)	0	0	0	2 (6)	0
Vomiting	1 (11)	0	1 (9)	0	0	0	2 (6)	0
Abdominal distension	1 (11)	0	0	0	0	0	1 (3)	0
Flatulence	0	0	1 (9)	0	0	0	1 (3)	0
Nervous system disorders	3 (33)	1 (11)	2 (18)	0	1 (8)	0	6 (19)	1 (3)
Paraesthesia	1 (11)	0	2 (18)	0	0	0	3 (9)	0
Neuropathy peripheral	1 (11) *	1 (11)	1 (9) *	0	0	0	2 (6) *	1 (3)
Dysgeusia	0	0	0	0	1 (8)	0	1 (3)	0
Neuralgia	1 (11)	0	0	0	0	0	1 (3)	0
Presyncope	1 (11)	0	0	0	0	0	1 (3)	0
Somnolence	1 (11)	0	0	0	0	0	1 (3)	0
Musculoskeletal and connective tissue disorders	0	0	3 (27)	0	1 (8)	0	4 (13)	0
Muscle spasms	0	0	3 (27)	0	1 (8)	0	4 (13)	0
Arthralgia	0	0	1 (9)	0	0	0	1 (3)	0
Muscle tightness	0	0	1 (9)	0	0	0	1 (3)	0
Psychiatric disorders	0	0	3 (27)	0	1 (8)	0	4 (13)	0
Hallucination	0	0	1 (9)	0	1 (8)	0	2 (6)	0
Insomnia	0	0	2 (18)	0	0	0	2 (6)	0
Confusional state	0	0	1 (9)	0	0	0	1 (3)	0
Investigations	0	0	0	1 (9)	1 (8)	1 (8)	1 (3)	2 (6)
Troponin T increased	0	0	0	0	2 (17)	0	2 (6)	0
Alanine aminotransferase increased	0	0	1 (9)	0	0	0	1 (3)	0
Aspartate aminotransferase increased	0	0	0	1 (9)	0	0	0	1 (3)
Lymphocyte count decreased	0	0	0	0	0	1 (8)	0	1 (3)
Platelet count decreased	0	0	0	0	1 (8)	0	1 (3)	0
Vascular disorders	0	1 (11)	0	2 (18)	0	0	0	3 (9)
Hypertension	0	0	0	2 (18)	0	0	0	2 (6)
Hypotension	0	1 (11)	0	0	0	0	0	1 (3)
Respiratory, thoracic and mediastinal disorders	0	0	2 (18)	0	0	0	2 (6)	0
Cough	0	0	1 (9)	0	0	0	1 (3)	0
Dyspnoea	0	0	1 (9)	0	0	0	1 (3)	0
Eye disorders	0	0	1 (9)	0	0	0	1 (3)	0
Vision blurred	0	0	1 (9)	0	0	0	1 (3)	0
Infections and infestations	1 (11)	0	0	0	0	0	1 (3)	0
Lip infection	1 (11)	0	0	0	0	0	1 (3)	0
Injury, poisoning and procedural complications	1 (11)	0	0	0	0	0	1 (3)	0
Vascular access complication	1 (11)	0	0	0	0	0	1 (3)	0
Skin and subcutaneous tissue disorders	1 (11)	0	0	0	0	0	1 (3)	0
Hyperhidrosis	1 (11)	0	0	0	0	0	1 (3)	0
Preferred terms (PTs) are coded according to MedDRA Version 19.0. ‘Related’ means possibly or probably related. A patient with multiple events within a PT is counted only once in the PT; the worst CTCAE grade is counted. * Peripheral sensory neuropathy.